Trial Profile
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 May 2021
Price :
$35
*
At a glance
- Drugs Mavrilimumab (Primary)
- Indications COVID-19 pneumonia; Inflammation; Respiratory insufficiency
- Focus Therapeutic Use
- 06 May 2021 Status changed from active, no longer recruiting to completed.
- 22 Dec 2020 According to a Kiniksa Pharmaceuticals media release, this study is also conducted at University of Cincinnati and Virginia Commonwealth University.
- 22 Dec 2020 According to a Kiniksa Pharmaceuticals media release, the company has closed the enrollment in this study early, as the company can focus on the registrational development program in the same patient population.